Lentechs -Creating A New Vision : APIOCTM-A New Generation of Soft, Suspended Contact Lens
Mr. Robin G. Sears, President & CEO
‘The fabulous forties’ in one’s life might not seem as fabulous after all, owing to several cognitive and physiological changes. One of the most universal changes is the onset of presbyopia, which causes near vision impairment with advancing age. One method to correct this visual problem is the use of contact lenses. However, due to complaints of visual compromise and discomfort, the majority of wearers tend to discontinue using even the most popular contact lenses. To have clearer vision, people with presbyopia often rely on reading glasses. As the condition progresses, the need to put glasses on every time to read something up close may become inconvenient. The pursuit of adopting new vision correction modalities such as wearing reading glasses with contact lenses, trying monovision, or switching to multifocal soft contact lenses results in a sustained decrease in presbyopes wearing contact lenses. Even though presbyopia-correcting soft contact lenses have evolved over the years, recent studies show only 14% of presbyopes use these lenses as their primary correction mode and nearly 70% of glasses-wearing presbyopes would prefer to wear contact lenses. This is mainly because current contact lens options result in visual compromise, presented as peripheral or near blur with center-near or center-distance designs additionally sacrificing distance vision quality for better vision up close.
Addressing this challenge is Lentechs, a privately held, clinical-stage ophthalmic medical device company. The company is focused on developing revolutionary soft, suspended contact lenses for all people suffering from presbyopia. Its breakthrough design includes unique, anatomically inspired features that allow free, translational eye movement behind a rotationally stable lens. “We are the first ones to disrupt the contact lens market in over 30 years with our new technology, APIOC. It is designed to work like progressive addition glasses so patients have exceptional vision correction at distance, intermediate, and near without having to compromise on their comfort or vision quality,” states Robin G. Sears, the President and CEO at Lentechs.
As a company, we want to bring about more innovation and breakthrough in the contact lens market to drive patients to eyecare professionals and deliver a new level of satisfaction as they age. We are focused on our novel design which has helped us gain several patents globally
APIOC is the brainchild of two optometrists and co-founders of Lentechs, Melissa D. Bailey, OD, Ph.D., and Joseph T. Barr, OD, MS, who sought to offer a reliable soft contact lens to presbyopes that delivers on vision. Eighty-two percent of optometrists who fit multifocal contact lenses state that it is somewhat challenging to find a solution for presbyopes. Furthermore, only 3% state that they can adequately address all of what patients want with current contact lens options. This leads to a negative impact on how they perceive current offerings. APIOC intends to provide the solution to these issues. The lenses were specifically designed to correct presbyopia, with or without astigmatism, addressing the urgent need in the marketplace.
Once inserted, APIOC is suspended from behind the upper eyelid above the lid wiper using its Stabilizing Crest.The Stabilizing Crest suspends the contact lens securely over the cornea, and together with two Balance Zones, helps maintain rotational stability and centration.The positioning of APIOC allows wearers to look through its center in a straight-ahead gaze for distance, and as the eye looks down, transitions for intermediate and near vision. This feature makes APIOC different than any other soft contact lens currently available. This revolutionary soft, suspended contact lens should beeasier for practitioners to fit and offer reliable vision for patients with comfort they can depend on.
Lentechs’sresearch program received a lot of positive feedback from both patients and practitioners. Eighty-eight percent of optometrists said they would use APIOC themselves ‑ and patients wanted to take the lenses home with them even after completing the trial. The company aims to complete its milestone clinical trials by the end of summer and launch in exclusive markets in early 2022, expanding rapidly thereafter “As a company, we want to bring about more innovation and breakthrough in the contact lens market to drive patients to eyecare professionals and deliver a new level of satisfaction as they age. We are focused on our novel design which has helped us gain several patents globally,” concludes Sears.
Description Lentechs is a privately held, clinical-stage ophthalmic medical device company focused on developing revolutionary soft, suspended contact lens, rooted in science-based innovation that will advance the care for patients with presbyopia. Its breakthrough design includes unique, anatomically inspired features that allow free, translational eye movement behind a rotationally stable lens. It is designed to work like progressive addition glasses so patients have exceptional vision correction at distance, intermediate, and near without having to compromise on their comfort or vision quality
This content is copyright protected
However, if you would like to share the information in this article, you may use the link below: